Oncolytic Virus Construction
Oncolytic virus is a group of virus that specifically infect and lyze tumor cells but not healthy cells. Creative Biolabs provides a broad range of oncolytic virus engineering scope including but not limit to Adenovirus, Herpes Simplex Virus, Measles Virus, Vaccinia Virus, Vescilar Stomatitis Virus, and Adeno-Associated Virus.
Adenovirus has been explored and engineered extensively as an oncolytic virus and viral vector for gene therapy to reduce viral virulence and increase efficacy and specificity. E1A gene in adenovirus is responsible for viral replication in tumor cells and need to be attenuated for oncolytic purpose. Coated protein modification is to increase target specificity of adenovirus to tumor cells, and thus alters viral tropism. Adenovirus can also be modified through transcriptional targeting, such as placing E1A and E1B gene under control of promoter of cyclooxygenase-2 enzyme (highly expressed in a range of cancers), or through post-transcriptional modification, such as targeting of cancer specific miRNA.
HSV is another group of virus that has been developed for cancer immunotherapy. Talimogene laherparepvec (T-Vec) is the first-in-class FDA approved oncolytic viral therapy that targets melanoma. Manipulation has been engineered before used as oncolytic viral vector. ICP34.5, a neurovirulence gene, has been deleted or partially deleted to allow the tumor-selective replication of the virus. Other engineering procedures include insertion of immune regulatory element Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) into the virus genome (T-Vec).
Vaccinia virus can also be engineered as oncolytic virus by mutation of Thymidine Kinase (TK) and Vaccinia Growth Factor (VGF) to attenuate the pathogenicity and increase tumor-specific replication. JX-594 is one of vaccinia virus strain expressing GM-CSF and showed promising clinical efficacy in phase I and Phase II trials.
Vesicular stomatitis virus is a negative single strand enveloped rhabdovirus. The enveloped glycoprotein mediates binding to tumor cells via cellular receptors, such as LDLR and LDL-like receptors.
Measles virus is a negative single strand RNA enveloped paramyxovirus. Live attenuated measles virus can be developed for oncolytic use. Measles virus hemagglutinin protein can bind to cellular receptors such as CD46, SLAM receptor and nectin-4 receptor.
Please feel free to contact us for a quote and further discussion with our scientists.
